Molecular and Cellular Biochemistry

, Volume 340, Issue 1–2, pp 107–114

Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation

  • Xiujuan Qu
  • Yingchun Li
  • Jing Liu
  • Ling Xu
  • Ye Zhang
  • Xuejun Hu
  • Kezuo Hou
  • Yunpeng Liu


The ubiquitin ligase Cbl-b is a negative regulator of the PI3K/Akt pathway, the survival pathway implicated in chemotherapy resistance. However, it remains unclear whether Cbl-b can regulate chemosensitivity through modulating Akt activation. In this study, VP-16-induced RBL-2H3 cells apoptosis was accompanied by the activation of Akt and ERK. The PI3K inhibitor LY294002, not the ERK inhibitor PD98059, enhanced the apoptosis. In addition, down-regulation of Cbl-b was also detected. Over expression of Cbl-b significantly enhanced VP-16-induced cell apoptosis with inhibition of Akt activity, while a dominant negative (DN) RING Finger domain mutation completely abolished this enhancement. On the other hand, ERK activity was enhanced by Cbl-b, and the ERK inhibitor PD98059 reversed Cbl-b-enhanced apoptosis. The consistent results were also showed in the process of Ara-c treatment. These observations indicate that Cbl-b promotes RBL-2H3 apoptosis induced by VP-16 or Ara-c, probably through inhibition of Akt and activation of ERK.


Cbl-b Chemosensitivity PI3K/Akt pathway ERK pathway 


  1. 1.
    Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70(4):219–224CrossRefPubMedGoogle Scholar
  2. 2.
    Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530CrossRefPubMedGoogle Scholar
  3. 3.
    Doepfner KT, Spertini O, Arcaro A (2007) Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21:1921–1930CrossRefPubMedGoogle Scholar
  4. 4.
    Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG (2008) A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 7(10):3141–3149CrossRefPubMedGoogle Scholar
  5. 5.
    Rømer MU, Larsen L, Offenberg H, Brünner N, Lademann UA (2008) Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia 10(10):1083–1091PubMedGoogle Scholar
  6. 6.
    Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, Grafone T, Martinelli G, Conte R, Martelli AM (2005) Deguelin, a PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 129(5):677–686CrossRefPubMedGoogle Scholar
  7. 7.
    Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68(15):6271–6280CrossRefPubMedGoogle Scholar
  8. 8.
    Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD (2002) Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene 21(9):1423–1433CrossRefPubMedGoogle Scholar
  9. 9.
    Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S (1995) Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10(12):2367–2377PubMedGoogle Scholar
  10. 10.
    Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S, Penninger JM (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403(6766):211–216CrossRefPubMedGoogle Scholar
  11. 11.
    Kitaura Y, Jang IK, Wang Y, Han YC, Inazu T, Cadera EJ et al (2007) Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 26(5):567–578CrossRefPubMedGoogle Scholar
  12. 12.
    Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, Gu H (2000) Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403(6766):216–220CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang R, Zhang N, Mueller DL (2008) Casitas B-lineage lymphoma b inhibits antigen recognition and slows cell cycle progression at late times during CD4+ T cell clonal expansion. J Immunol 181(8):5331–5339PubMedGoogle Scholar
  14. 14.
    Qu X, Sada K, Kyo S, Maeno K, Miah SM, Yamamura H (2008) Negative regulation of FcepsilonRI-mediated mast cell activation by a ubiquitin-protein ligase Cbl-b. Blood 103(5):1779–1786CrossRefGoogle Scholar
  15. 15.
    Qu X, Liu Y, Ma Y, Zhang Y, Li Y, Hou K (2008) Up-regulation of the Cbl family of ubiquitin ligases is involved in ATRA and bufalin- induced cell adhesion but not cell differentiation. Biochem Biophys Res Commun 367(1):183–189CrossRefPubMedGoogle Scholar
  16. 16.
    Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ, Marburger TB, Wen J, Perrotti D, Bloomfield CD, Whitman SP (2007) Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 110(3):1022–1024CrossRefPubMedGoogle Scholar
  17. 17.
    Gustin SE, Thien CB, Langdon WY (2006) Cbl-b is a negative regulator of inflammatory cytokines produced by IgE-activated mast cells. J Immunol 177(9):5980–5989PubMedGoogle Scholar
  18. 18.
    Fang D, Wang HY, Fang N, Altman Y, Elly C, Liu YC (2001) Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem 276(7):4872–4878CrossRefPubMedGoogle Scholar
  19. 19.
    Fang D, Liu YC (2001) Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2(9):870–875CrossRefPubMedGoogle Scholar
  20. 20.
    Xu J, Zhou JY, Tainsky MA, Wu GS (2007) Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res 67(3):1203–1211CrossRefPubMedGoogle Scholar
  21. 21.
    Qu X, Zhang Y, Li Y, Hu X, Xu Y, Xu L, Hou K, Sada K, Liu Y (2009) Ubiquitin ligase Cbl-b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals. FEBS Lett 583(13):2255–2262CrossRefPubMedGoogle Scholar
  22. 22.
    Lee ER, Ahn JY, Kang YJ, Kim BW, Cho SG (2006) Interplay between PI3K/AKT and MAPK signalling pathways in DNA damaging drug-induced apoptosis. Biochim Biophys Acta 1763(9):958–968CrossRefPubMedGoogle Scholar
  23. 23.
    Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, Zhang J, Sada K, Liu Y (2009) Reversal of P-glycoprotein- mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol 218(2):248–255CrossRefPubMedGoogle Scholar
  24. 24.
    Morley N, Rapp A, Dittmar H, Salter L, Gould D, Greulich KO, Curnow A (2006) UVA-induced apoptosis studied by the new apo/necro-Comet-assay which distinguishes viable, apoptotic and necrotic cells. Mutagenesis 21(2):105–114CrossRefPubMedGoogle Scholar
  25. 25.
    Lee ER, Kang YJ, Kim JH, Lee HT, Cho SG (2005) Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem 280(36):31498–31507CrossRefPubMedGoogle Scholar
  26. 26.
    Lee SH, Fujita N, Imai K, Tsuruo T (1995) Cysteine produced from lymph node stromal cells suppresses apoptosis of mouse malignant T-lymphoma cells. Biochem Biophys Res Commun 213(3):837–844CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Xiujuan Qu
    • 1
  • Yingchun Li
    • 1
  • Jing Liu
    • 1
  • Ling Xu
    • 1
  • Ye Zhang
    • 1
  • Xuejun Hu
    • 2
  • Kezuo Hou
    • 1
  • Yunpeng Liu
    • 1
  1. 1.Department of Medical OncologyThe First Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Respiratory MedicineThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations